48,830
edits
(→Gross: +DDx) |
m (→General) |
||
Line 387: | Line 387: | ||
*In a grouping known as ''neuoblastic tumours'' which includes:<ref name=pmid10421272>{{cite journal |author=Shimada H, Ambros IM, Dehner LP, Hata J, Joshi VV, Roald B |title=Terminology and morphologic criteria of neuroblastic tumors: recommendations by the International Neuroblastoma Pathology Committee |journal=Cancer |volume=86 |issue=2 |pages=349–63 |year=1999 |month=July |pmid=10421272 |doi= |url=}}</ref> | *In a grouping known as ''neuoblastic tumours'' which includes:<ref name=pmid10421272>{{cite journal |author=Shimada H, Ambros IM, Dehner LP, Hata J, Joshi VV, Roald B |title=Terminology and morphologic criteria of neuroblastic tumors: recommendations by the International Neuroblastoma Pathology Committee |journal=Cancer |volume=86 |issue=2 |pages=349–63 |year=1999 |month=July |pmid=10421272 |doi= |url=}}</ref> | ||
**[[Ganglioneuroma]] (benign). | **[[Ganglioneuroma]] (benign). | ||
** | **[[Ganglioneuroblastoma]] (intermediate). | ||
**Neuroblastoma (aggressive). | **Neuroblastoma (aggressive). | ||
===Gross=== | ===Gross=== | ||
*~40% of in the [[adrenal gland]].<ref>{{Ref PCPBoD8|253}}</ref> | *~40% of in the [[adrenal gland]].<ref>{{Ref PCPBoD8|253}}</ref> |
edits